I am not certain if my reply on NYT was incomplete

I am not certain if my reply on NYT was incomplete , is just what I copied to share here.

Just to be safe, I replied once more to mockingjay:

@mockingjay

In a double blinded,
placebo controlled study, Leronlimab demonstrated statistically significant improvement in NEWS2 (National Early Warning Score), a widely accepted UK clinical metric for measuring the progression of COVID into the severe/critical phase. (P=0.02). Leronlimab increased the number of patients who showed clinical improvement in the NEWS2 score, by 150%.

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

https://clinicaltrials.gov/ct2/show/NCT043436...amp;rank=3

The MOA for leronlimab reducing viremia, reversing cytokine storm and restoring immune function has need described by Dr. Bruce Patterson, a virologist formerly at Stanford.

Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277012/

This should be sufficient to demonstrate this is real. You can go to Cytodyn.com, but these other sources are independent.